FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885208058> ?p ?o ?g. }

• W2885208058 endingPage "3764" @default.
• W2885208058 startingPage "3764" @default.
• W2885208058 abstract "Abstract Background: RXC004, a potent and selective porcupine (PORCN) inhibitor, is being investigated in a safety and tolerability study in cancer patients with solid tumours (CT 2017-000720-98). In addition to the tumour targeting role of RXC004 and other Wnt pathway inhibitors, we present pre-clinical data which suggests further potential for RXC004 in modulating the immune system of the tumour microenvironment. Materials and Methods: To evaluate the potential of a novel porcupine inhibitor, RXC004, as an immunomodulatory anti-cancer agent, sub cutaneous B16F10 melanoma (C57BL/6 mice) and CT26 colorectal (BALB/c mice) murine tumour models were utilised. Mice in both models were treated with RXC004 alone or in combination with mouse anti-PD-1 antibody. Flow cytometry analysis was utilised to measure key immune cell populations in the tumour microenvironment. To probe the underlying mechanism of immune modulation in these models and to provide a link to the emerging clinical data suggesting a role for Wnt pathway activation in immune escape, human monocytic cells were isolated from PBMCs and human dendritic cells were derived in vitro. The Wnt pathway was induced in derived Dendritic cells and expression of IDO was measured. Results: In the murine CT26 model, RXC004 treatment reduced tumour size when dosed in combination with anti-PD-1 antibody, causing regression and cures in some animals. Furthermore, flow cytometry showed RXC004 in combination with anti-PD-1 antibody increased the proportion of CD8+ cytotoxic T cells as well as decreasing FoxP3+ regulatory T cells when compared to the monotherapy anti-PD-1 arm. In a syngeneic murine melanoma B16F10 model, RXC004 monotherapy at a dose of 5mg/kg QD orally significantly inhibited tumour growth, as did RXC004 combined with anti-PD-1. RXC004 had no effect on the proliferation of B16F10 cells in vitro, suggesting this was not caused by the compound directly affecting B16 cell proliferation. Flow cytometry analysis of the B16 tumours showed significant immune modulatory effects in the tumour microenvironment. In addition to mouse model data, Wnt pathway activation in human dendritic cells was shown to increase IDO expression. Conclusion: Taken together, data from murine syngeneic mouse models corroborate literature data suggesting that inhibiting the Wnt pathway may promote the immune response against human cancers. Citation Format: Inder Bhamra, Richard Armer, Matilda Bingham, Catherine Eagle, Alicia Edmenson Cook, Caroline Phillips, Simon Woodcock. Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3764." @default.
• W2885208058 created "2018-08-22" @default.
• W2885208058 creator A5003246050 @default.
• W2885208058 creator A5045023434 @default.
• W2885208058 creator A5055499083 @default.
• W2885208058 creator A5063198530 @default.
• W2885208058 creator A5066339819 @default.
• W2885208058 creator A5081842675 @default.
• W2885208058 creator A5082399428 @default.
• W2885208058 date "2018-07-01" @default.
• W2885208058 modified "2023-10-02" @default.
• W2885208058 title "Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer" @default.
• W2885208058 doi "https://doi.org/10.1158/1538-7445.am2018-3764" @default.
• W2885208058 hasPublicationYear "2018" @default.
• W2885208058 type Work @default.
• W2885208058 sameAs 2885208058 @default.
• W2885208058 citedByCount "7" @default.
• W2885208058 countsByYear W28852080582019 @default.
• W2885208058 countsByYear W28852080582020 @default.
• W2885208058 countsByYear W28852080582021 @default.
• W2885208058 countsByYear W28852080582022 @default.
• W2885208058 countsByYear W28852080582023 @default.
• W2885208058 crossrefType "journal-article" @default.
• W2885208058 hasAuthorship W2885208058A5003246050 @default.
• W2885208058 hasAuthorship W2885208058A5045023434 @default.
• W2885208058 hasAuthorship W2885208058A5055499083 @default.
• W2885208058 hasAuthorship W2885208058A5063198530 @default.
• W2885208058 hasAuthorship W2885208058A5066339819 @default.
• W2885208058 hasAuthorship W2885208058A5081842675 @default.
• W2885208058 hasAuthorship W2885208058A5082399428 @default.
• W2885208058 hasConcept C121608353 @default.
• W2885208058 hasConcept C137620995 @default.
• W2885208058 hasConcept C154317977 @default.
• W2885208058 hasConcept C159654299 @default.
• W2885208058 hasConcept C167672396 @default.
• W2885208058 hasConcept C202751555 @default.
• W2885208058 hasConcept C203014093 @default.
• W2885208058 hasConcept C2776107976 @default.
• W2885208058 hasConcept C2779727006 @default.
• W2885208058 hasConcept C502942594 @default.
• W2885208058 hasConcept C54355233 @default.
• W2885208058 hasConcept C553184892 @default.
• W2885208058 hasConcept C55493867 @default.
• W2885208058 hasConcept C62478195 @default.
• W2885208058 hasConcept C86803240 @default.
• W2885208058 hasConcept C8891405 @default.
• W2885208058 hasConcept C95444343 @default.
• W2885208058 hasConcept C96232424 @default.
• W2885208058 hasConceptScore W2885208058C121608353 @default.
• W2885208058 hasConceptScore W2885208058C137620995 @default.
• W2885208058 hasConceptScore W2885208058C154317977 @default.
• W2885208058 hasConceptScore W2885208058C159654299 @default.
• W2885208058 hasConceptScore W2885208058C167672396 @default.
• W2885208058 hasConceptScore W2885208058C202751555 @default.
• W2885208058 hasConceptScore W2885208058C203014093 @default.
• W2885208058 hasConceptScore W2885208058C2776107976 @default.
• W2885208058 hasConceptScore W2885208058C2779727006 @default.
• W2885208058 hasConceptScore W2885208058C502942594 @default.
• W2885208058 hasConceptScore W2885208058C54355233 @default.
• W2885208058 hasConceptScore W2885208058C553184892 @default.
• W2885208058 hasConceptScore W2885208058C55493867 @default.
• W2885208058 hasConceptScore W2885208058C62478195 @default.
• W2885208058 hasConceptScore W2885208058C86803240 @default.
• W2885208058 hasConceptScore W2885208058C8891405 @default.
• W2885208058 hasConceptScore W2885208058C95444343 @default.
• W2885208058 hasConceptScore W2885208058C96232424 @default.
• W2885208058 hasIssue "13_Supplement" @default.
• W2885208058 hasLocation W28852080581 @default.
• W2885208058 hasOpenAccess W2885208058 @default.
• W2885208058 hasPrimaryLocation W28852080581 @default.
• W2885208058 hasRelatedWork W1572283981 @default.
• W2885208058 hasRelatedWork W1914453902 @default.
• W2885208058 hasRelatedWork W1991837516 @default.
• W2885208058 hasRelatedWork W2885274281 @default.
• W2885208058 hasRelatedWork W3048051248 @default.
• W2885208058 hasRelatedWork W3180719608 @default.
• W2885208058 hasRelatedWork W3189892794 @default.
• W2885208058 hasRelatedWork W4283731173 @default.
• W2885208058 hasRelatedWork W4286560817 @default.
• W2885208058 hasRelatedWork W2079932508 @default.
• W2885208058 hasVolume "78" @default.
• W2885208058 isParatext "false" @default.
• W2885208058 isRetracted "false" @default.
• W2885208058 magId "2885208058" @default.
• W2885208058 workType "article" @default.